Gufic Biosciences Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Gufic Biosciences.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	17.1%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

We Think You Should Be Aware Of Some Concerning Factors In Gufic Biosciences' (NSE:GUFICBIO) Earnings

Jun 06

Is Gufic Biosciences (NSE:GUFICBIO) Using Too Much Debt?

Jun 17

These 4 Measures Indicate That Gufic Biosciences (NSE:GUFICBIO) Is Using Debt Reasonably Well

Sep 02

Should You Be Adding Gufic Biosciences (NSE:GUFICBIO) To Your Watchlist Today?

May 07

Here's Why I Think Gufic Biosciences (NSE:GUFICBIO) Is An Interesting Stock

Dec 07

This Is The Reason Why We Think Gufic Biosciences Limited's (NSE:GUFICBIO) CEO Might Be Underpaid

Sep 15

Is Now The Time To Put Gufic Biosciences (NSE:GUFICBIO) On Your Watchlist?

Aug 12

Gufic Biosciences' (NSE:GUFICBIO) Performance Is Even Better Than Its Earnings Suggest

Jun 11

If You Like EPS Growth Then Check Out Gufic Biosciences (NSE:GUFICBIO) Before It's Too Late

Mar 19

What Percentage Of Gufic Biosciences Limited (NSE:GUFICBIO) Shares Do Insiders Own?

Mar 01

Here's What Gufic Biosciences Limited's (NSE:GUFICBIO) Shareholder Ownership Structure Looks Like

Dec 01

Gufic Biosciences (NSE:GUFICBIO) Has A Somewhat Strained Balance Sheet

Nov 13

The Gufic Biosciences (NSE:GUFICBIO) Share Price Has Gained 116%, So Why Not Pay It Some Attention?

Oct 19

Can Gufic Biosciences Limited's (NSE:GUFICBIO) ROE Continue To Surpass The Industry Average?

Sep 14

I Built A List Of Growing Companies And Gufic Biosciences (NSE:GUFICBIO) Made The Cut

Aug 24

Investors Appear Satisfied With Gufic Biosciences Limited's (NSE:GUFICBIO) Prospects

Aug 03

Earnings Tell The Story For Gufic Biosciences Limited (NSE:GUFICBIO)

Jul 09

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Gufic Biosciences no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NSEI:GUFICBIO - Estimaciones futuras de los analistas y datos financieros pasados (INR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2024	8,067	861	-1,202	-75	N/A
12/31/2023	7,847	842	N/A	N/A	N/A
9/30/2023	7,604	823	-1,639	159	N/A
6/30/2023	7,204	793	N/A	N/A	N/A
3/31/2023	6,906	797	-2,142	-266	N/A
12/31/2022	6,798	819	N/A	N/A	N/A
9/30/2022	6,744	826	-1,652	-355	N/A
6/30/2022	6,937	857	N/A	N/A	N/A
3/31/2022	7,792	958	188	1,062	N/A
12/31/2021	7,489	884	N/A	N/A	N/A
9/30/2021	7,434	829	1,662	1,798	N/A
6/30/2021	6,777	769	N/A	N/A	N/A
3/31/2021	4,877	442	749	873	N/A
12/31/2020	4,005	305	N/A	N/A	N/A
9/30/2020	3,538	243	-14	511	N/A
6/30/2020	3,195	123	N/A	N/A	N/A
3/31/2020	3,788	227	73	471	N/A
12/31/2019	3,681	243	N/A	N/A	N/A
9/30/2019	3,580	232	4	254	N/A
6/30/2019	3,640	249	N/A	N/A	N/A
3/31/2019	3,508	219	-79	52	N/A
12/31/2018	3,334	164	N/A	N/A	N/A
9/30/2018	3,353	168	N/A	N/A	N/A
6/30/2018	3,192	164	N/A	N/A	N/A
3/31/2018	3,056	165	-131	-48	N/A
12/31/2017	2,887	181	N/A	N/A	N/A
9/30/2017	2,651	154	N/A	N/A	N/A
6/30/2017	2,544	124	N/A	N/A	N/A
3/31/2017	2,455	90	N/A	-41	N/A
12/31/2016	2,419	105	N/A	N/A	N/A
9/30/2016	2,329	98	N/A	N/A	N/A
6/30/2016	2,201	88	N/A	N/A	N/A
3/31/2016	2,022	73	N/A	-43	N/A
12/31/2015	1,806	62	N/A	N/A	N/A
9/30/2015	1,588	45	N/A	N/A	N/A
6/30/2015	1,500	36	N/A	N/A	N/A
3/31/2015	1,516	42	N/A	112	N/A
12/31/2014	1,533	43	N/A	N/A	N/A
9/30/2014	1,503	47	N/A	N/A	N/A
6/30/2014	1,366	47	N/A	N/A	N/A
3/31/2014	1,230	43	N/A	109	N/A
12/31/2013	1,104	37	N/A	N/A	N/A
9/30/2013	1,037	35	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de GUFICBIO es superior a la tasa de ahorro (6.7%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de GUFICBIO crezcan más rápidamente que el mercado Indian

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de GUFICBIO crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de GUFICBIO crezcan más rápidamente que el mercado de Indian.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de GUFICBIO crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de GUFICBIO se prevé que sea elevada dentro de 3 años.

Gufic Biosciences Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Gufic Biosciences Limited Announces Cessation of Rabi Sahoo as Independent Director and Chairman of Stakeholders Relationship Committee and Member of Audit Committee

Investor sentiment improves as stock rises 19%

We Think You Should Be Aware Of Some Concerning Factors In Gufic Biosciences' (NSE:GUFICBIO) Earnings

Gufic Biosciences Limited Proposes Recommendation of Final Dividend for the Financial Year 2023-24

Full year 2024 earnings released: EPS: ₹8.74 (vs ₹8.22 in FY 2023)

Third quarter 2024 earnings released: EPS: ₹2.23 (vs ₹2.10 in 3Q 2023)

Second quarter 2024 earnings released: EPS: ₹2.39 (vs ₹2.09 in 2Q 2023)

Gufic Biosciences Limited announced that it has received INR 999.9 million in funding from Motilal Oswal Financial Services Limited

Upcoming dividend of ₹0.10 per share

Gufic Biosciences Limited to Report Q2, 2024 Results on Nov 14, 2023

Gufic Biosciences Limited, Annual General Meeting, Sep 29, 2023

New minor risk - Shareholder dilution

Gufic Biosciences Limited, Annual General Meeting, Sep 29, 2023

First quarter 2024 earnings released: EPS: ₹2.13 (vs ₹2.17 in 1Q 2023)

Gufic Biosciences Limited to Report Q1, 2024 Results on Aug 11, 2023

Is Gufic Biosciences (NSE:GUFICBIO) Using Too Much Debt?

Investor sentiment improves as stock rises 17%

Gufic Biosciences Limited Recommends Dividend for the Financial Year Ended March 31, 2023

Full year 2023 earnings released: EPS: ₹8.22 (vs ₹9.89 in FY 2022)

Third quarter 2023 earnings released: EPS: ₹2.10 (vs ₹2.17 in 3Q 2022)

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹2.09 (vs ₹2.41 in 2Q 2022)

Second quarter 2023 earnings released: EPS: ₹2.09 (vs ₹2.41 in 2Q 2022)

Gufic Biosciences Limited Approves Final Dividend for the Financial Year Ended March 31, 2022

These 4 Measures Indicate That Gufic Biosciences (NSE:GUFICBIO) Is Using Debt Reasonably Well

Upcoming dividend of ₹0.10 per share

First quarter 2023 earnings released: EPS: ₹2.17 (vs ₹3.22 in 1Q 2022)

Gufic Biosciences Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022

Gufic Biosciences Limited, Annual General Meeting, Sep 02, 2022

Gufic Biosciences Limited to Report Q1, 2023 Results on Aug 11, 2022

Investor sentiment improved over the past week

Gufic Biosciences Limited Launches New Drug Delivery System

Full year 2022 earnings released: EPS: ₹9.89 (vs ₹4.56 in FY 2021)

Gufic Biosciences Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022

Should You Be Adding Gufic Biosciences (NSE:GUFICBIO) To Your Watchlist Today?

Now 21% undervalued

Gufic Biosciences Limited Receives Permission from CDSCO to Manufacture and Sale Isavuconazonium Sulfate API and Finished Formulation Isavuconazole for Injection 200 Mg/Vial

Now 21% undervalued

Gufic Biosciences Limited Receives DCGI Nod for Thymosin Alpha - 1

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Here's Why I Think Gufic Biosciences (NSE:GUFICBIO) Is An Interesting Stock

Second quarter 2022 earnings released: EPS ₹2.41 (vs ₹2.10 in 2Q 2021)

This Is The Reason Why We Think Gufic Biosciences Limited's (NSE:GUFICBIO) CEO Might Be Underpaid

Upcoming dividend of ₹0.10 per share

Is Now The Time To Put Gufic Biosciences (NSE:GUFICBIO) On Your Watchlist?

Investor sentiment improved over the past week

Gufic Biosciences' (NSE:GUFICBIO) Performance Is Even Better Than Its Earnings Suggest

Full year 2021 earnings released: EPS ₹4.56 (vs ₹2.94 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

If You Like EPS Growth Then Check Out Gufic Biosciences (NSE:GUFICBIO) Before It's Too Late

What Percentage Of Gufic Biosciences Limited (NSE:GUFICBIO) Shares Do Insiders Own?

Gufic Biosciences (NSE:GUFICBIO) Has A Pretty Healthy Balance Sheet

Third quarter 2021 earnings released: EPS ₹1.69 (vs ₹0.90 in 3Q 2020)

Gufic Biosciences Limited to Report Q3, 2021 Results on Feb 08, 2021

Is Gufic Biosciences' (NSE:GUFICBIO) 164% Share Price Increase Well Justified?

Why Gufic Biosciences Limited (NSE:GUFICBIO) Looks Like A Quality Company

Investor sentiment improved over the past week

New 90-day high: ₹131

Here's Why I Think Gufic Biosciences (NSE:GUFICBIO) Is An Interesting Stock

Here's What Gufic Biosciences Limited's (NSE:GUFICBIO) Shareholder Ownership Structure Looks Like

Gufic Biosciences (NSE:GUFICBIO) Has A Somewhat Strained Balance Sheet

Second quarter 2021 earnings released: EPS ₹2.10

Upcoming Dividend of ₹0.05 Per Share

The Gufic Biosciences (NSE:GUFICBIO) Share Price Has Gained 116%, So Why Not Pay It Some Attention?

First quarter earnings released

Can Gufic Biosciences Limited's (NSE:GUFICBIO) ROE Continue To Surpass The Industry Average?

I Built A List Of Growing Companies And Gufic Biosciences (NSE:GUFICBIO) Made The Cut

Full year earnings released - EPS ₹2.94

Investors Appear Satisfied With Gufic Biosciences Limited's (NSE:GUFICBIO) Prospects

Gufic Biosciences Limited to Report Q4, 2020 Results on Jul 31, 2020

Earnings Tell The Story For Gufic Biosciences Limited (NSE:GUFICBIO)